Filing search / Kineta, Inc. / "Gender"

8-K

EX-99.2

KANT Kineta, Inc.

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

Gender (n %) Female 1 (50) 4 (80) 2 (50) 1 (25) 2 (50) 1 (33) 2 (40) 13 (48) Male 1 (50) 1 (20) 2 (50) 3 (75) 2 (50) 2 (67) 3 (60) 14 (52) Race (n

8-K

EX-99.1

KANT Kineta, Inc.

5 Jan 24

Regulation FD Disclosure

4:30pm

pembro 400mg Q6W VISTA-101: Baseline patient characteristics (monotherapy) Characteristic Statistic Result Gender N (%) Male Female 7 (47) 8 (53) Race

8-K

EX-99.2

KANT Kineta, Inc.

6 Nov 23

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

8:30am

presentation at SITC 2023 VISTA-101: Baseline patient characteristics Characteristic Statistic Result Gender N (%) Male Female 7 (64) 4 (36) Race/Ethnicity N

425

3bxbdpfpvp s4smia65

6 Jun 22

Business combination disclosure

4:05pm

8-K

EX-2.3

n8l 12ankxft5f2

6 Jun 22

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

4:02pm

8-K

EX-2.4

r2c1mfb1 ygt3wxiobkc

6 Jun 22

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

4:02pm

8-K

EX-2.2

2qibanwq5gv36 qeqj

6 Jun 22

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

4:02pm

8-K

EX-10.1

5aj3bvts8hd qfb

30 Dec 20

Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics

4:44pm

S-4

EX-2.4

qa0h7

23 Sep 20

Registration of securities issued in business combination transactions

4:50pm